⚕️ As cannabidiol (CBD) products proliferate in the consumer wellness market with limited regulatory oversight, healthcare providers should recognize that commercial CBD gummies and similar formulations lack standardized dosing, quality assurance, and rigorous efficacy data comparable to prescription medications. While some observational data suggest potential benefits for anxiety, sleep, and pain, most claims remain supported only by preclinical or anecdotal evidence rather than large-scale clinical trials, and many products contain unlabeled contaminants or inaccurate cannabinoid concentrations. The absence of FDA approval for CBD as a dietary supplement or wellness ingredient, combined with variable state-level regulations and the potential for drug-drug interactions through cytochrome P450 inhibition, introduces significant uncertainty when patients self-medicate with these products. Given these limitations, clinicians should ask patients about CBD use during medication reconciliation, counsel them on the lack of established safety and efficacy